The company and TScan Therapeutics have entered into a research collaboration and license agreement to explore development of TCR-T cell therapies for the treatment of COVID-19.
The allo T-cell platform will be used in combination with TScan's immunodominant epitopes and TCR sequences for the development and commercialisation of TCR-T cell therapies.
Market Data 
Markets 
AI
